JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zelis, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zelis, R.

Relative presynaptic and postsynaptic effects of urapidil on adrenoceptors in the rabbit pulmonary artery

R Zelis

Urapidil is a new antihypertensive drug which is thought to possess unique antiadrenergic properties. It is definitely a post-synaptic alpha adrenergic antagonist, but it also claimed to be a presynaptic alpha adrenergic agonist resulting in inhibition of norepinephrine release. To test the relative presynaptic and postsynaptic activity and selectivity in an isolated rabbit pulmonary arterial preparation, two series of studies were performed. The first evaluated the effects of urapidil on electrically evoked 3H overflow in the superfused vascular strip preincubated with [3H]norepinephrine. No significant inhibition of 3H overflow was observed. Rather, urapidil appeared to possess relatively weak presynaptic alpha-2 adrenergic antagonistic properties which were reversed by clonidine. The concentration producing a 30% increase in 3H overflow (EC30pre) was 7070 nM. The second series of studies evaluated the effects of urapidil on the concentration- contractile response curve to norepinephrine. Schild plot analysis yielded a pA2 value of 6.24 and a KBpost of 575 nM. One measure of the relative pre- and postsynaptic antagonistic potency is the EC30pre/KBpost ratio. For urapidil, this was 12.3, suggesting that the drug is a partially selective postsynaptic alpha adrenergic antagonist, with approximately 4.5 times the postsynaptic selectivity of phentolamine, but with 1/18 the potency of phentolamine to block postsynaptic alpha receptors.

Volume 237, Issue 3, pp. 746-749, 06/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1986 by the American Society for Pharmacology and Experimental Therapeutics.